Advances in Central Nervous System Tumor Classification

Malta, Tathiane; Snyder, James M.; Noushmehr, Houtan; Castro, Ana Valéria

doi:10.1007/978-3-031-29750-2_10

Cited by 3 publications

(1 citation statement)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The World Health Organization (WHO) classification of central nervous system (CNS) tumors now requires the integration of histopathology and molecular genetics demonstrating the need for molecular characterization clinically ( 1 ). With the advent of precision medicine in oncology, wherein targetable mutations are identified for therapies, the application of next-generation sequencing will continue to expand.…”

Section: Introductionmentioning

confidence: 99%

Long-read sequencing for brain tumors

Shelton,

Zandpazandi,

Nix

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Brain tumors and genomics have a long-standing history given that glioblastoma was the first cancer studied by the cancer genome atlas. The numerous and continuous advances through the decades in sequencing technologies have aided in the advanced molecular characterization of brain tumors for diagnosis, prognosis, and treatment. Since the implementation of molecular biomarkers by the WHO CNS in 2016, the genomics of brain tumors has been integrated into diagnostic criteria. Long-read sequencing, also known as third generation sequencing, is an emerging technique that allows for the sequencing of longer DNA segments leading to improved detection of structural variants and epigenetics. These capabilities are opening a way for better characterization of brain tumors. Here, we present a comprehensive summary of the state of the art of third-generation sequencing in the application for brain tumor diagnosis, prognosis, and treatment. We discuss the advantages and potential new implementations of long-read sequencing into clinical paradigms for neuro-oncology patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Long-read sequencing for brain tumors

Shelton,

Zandpazandi,

Nix

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

WHO Classification of CNS Tumors (General Principles)

Atallah,

Alahmed,

Algabri

et al. 2024

Surgical Neuro-Oncology

View full text Add to dashboard Cite

The Activity of 1,8-Dihydroanthraquinone Derivatives in Nervous System Cancers

Okoń,

Kukula-Koch,

Jarząb

et al. 2024

Molecules

View full text Add to dashboard Cite

Primary and metastatic tumors of the nervous system represent a diverse group of neoplasms, each characterized by distinct biological features, prognostic outcomes, and therapeutic approaches. Due to their molecular complexity and heterogeneity, nervous system cancers (NSCs) pose significant clinical challenges. For decades, plants and their natural products with established anticancer properties have played a pivotal role in the treatment of various medical conditions, including cancers. Anthraquinone derivatives, a class of tricyclic secondary metabolites, are found in several botanical families, such as Fabaceae, Polygonaceae, Rhamnaceae, and Rubiaceae. In a comprehensive review, recent advancements in the anticancer properties of 1,8-dihydroanthraquinone derivatives—such as emodin, aloe-emodin, hypericin, chrysophanol, rhein, and physcion—were analyzed. These compounds have been studied extensively, both used individually and in combination with other chemotherapeutic agents, using in vitro and in vivo models of nervous system tumors. It was demonstrated that 1,8-dihydroanthraquinone derivatives induce apoptosis and necrosis in cancerous cells, intercalate into DNA, disrupting transcription and replication in rapidly dividing cells, and alter ROS levels, leading to oxidative stress that damages tumor cells. Additionally, they can influence signaling pathways involved in oncogenesis, such as MAPK, PI3K/Akt, or others crucial for the survival and the proliferation of NSC cells. The exploration of 1,8-dihydroanthraquinone derivatives aims to develop novel therapies that could overcome resistance and improve cancer patients’ outcomes.

show abstract

Advances in Central Nervous System Tumor Classification

Cited by 3 publications

References 109 publications

Long-read sequencing for brain tumors

Long-read sequencing for brain tumors

WHO Classification of CNS Tumors (General Principles)

The Activity of 1,8-Dihydroanthraquinone Derivatives in Nervous System Cancers

Contact Info

Product

Resources

About